Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Fibronectin type III domain" patented technology

The Fibronectin type III domain is an evolutionary conserved protein domain that is widely found in animal proteins. The fibronectin protein in which this domain was first identified contains 16 copies of this domain. The domain is about 100 amino acids long and possesses a beta sandwich structure. Of the three fibronectin-type domains, type III is the only one without disulfide bonding present. Fibronectin domains are found in a wide variety of extracellular proteins. They are widely distributed in animal species, but also found sporadically in yeast, plant and bacterial proteins.

Protein scaffolds for antibody mimics and other binding proteins

Disclosed herein are proteins that include a fibronectin type III domain having at least one randomized loop. Also disclosed herein are nucleic acids encoding such proteins and the use of such proteins in diagnostic methods and in methods for evolving novel compound-binding species and their ligands.
Owner:BRISTOL MYERS SQUIBB CO

Fibronectin type iii domain-based multimeric scaffolds

The present invention provides fibronectin type III (Fn3)-based multimeric scaffolds that specifically bind to one or more specific target antigen. The invention further provides bispecific Fn3-derived binding molecules that bind to two or more target antigens simultaneously, fusions, conjugates, and methods to increase the stability of Fn3-based binding molecules. Furthermore, the present invention is related to a prophylactic, therapeutic or diagnostic agent, which contains Fn3-based multimeric scaffolds.
Owner:MEDIMMUNE LLC

Serum albumin binding molecules

The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
Owner:BRISTOL MYERS SQUIBB CO

Method for building N-glycosylation efficiency detection receptor protein models in Escherichia coli by aid of skeleton proteins Fn3 (fibronectin type III domain)

The invention belongs to the field of biotechnologies, and relates to a method for applying recombinant expression separated and purified human-derived protein Fn3 (fibronectin type III domain) mutants as N-glycosylation efficiency detection model proteins. The method includes steps of constructing Fn3-Gly-loop recombinant protein gene expression vectors of the Fn3 mutants; jointly transforming the constructed expression vectors into Escherichia coli engineering strains CLM37 by means of electric shock processes; screening the expression vectors by the aid of antibiotics to obtain positive clones. Recombinant proteins contain Fn3-Gly-loop proteins which are about to be modified by recombinant glycosyl, and the Fn3-Gly-loop fusion protein glycosylation efficiency can be detected by the aid of Western Blot processes. The method has the advantages that the skeleton proteins Fn3 in Escherichia coli are used as receptor proteins, accordingly, the model receptor proteins suitable for N-glycosylation modification efficiency research can be constructed, and the recombinant protein glycosylation efficiency can be easily, quickly and efficiently detected in the Escherichia coli.
Owner:DALIAN UNIV

Bispecific egfr/igfir binding molecules

The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
Owner:BRISTOL MYERS SQUIBB CO

Method for preparing antigen substitute by using human fibronectin type III domain to display two antigenic epitopes

The present invention discloses a method for preparing an antigen substitute by using human fibronectin type III domain (Fn3) to display two antigenic epitopes. According to the method, through gene recombination, base sequences for encoding two antigenic epitopes are respectively recombined at the FG loop region and the 3' terminal of the sequence encoding Fn3 gene to from an Fn3 and double antigenic epitope fusion gene; and the fusion protein displaying the double antigenic epitope is efficiently and rapidly expressed and prepared with an Escherichia coli expression system. According to thepresent invention, the antigen substitute displaying the double antigenic epitopes can be simply, rapidly and efficiently prepared so as to establish the technical platform for the production of the corresponding immunological assay.
Owner:DALIAN UNIV

Chimeric Antigen Receptors Comprising BCMA-specific Fibronectin Type III Domains and Uses Thereof

ActiveUS20190330361A1Stable and controllable CAR moleculesEasy to optimizeFibrinogenAntibody mimetics/scaffoldsAntigenAntigen receptors
BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.
Owner:JANSSEN BIOTECH INC

Fast-off rate serum albumin binding fibronectin type III domains

Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
Owner:BRISTOL MYERS SQUIBB CO

Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc

The present invention relates to DCC-fusion proteins, nucleic acid molecules encoding the DCC-fusion proteins, as well as methods for their production and their use in treatment of cancer such as colorectal cancer, NSCLC and metastatic breast cancer. The present invention also relates to methods of treating cancer such as colorectal cancer, NSCLC and metastatic breast cancer by administering DCC-fusion proteins.
Owner:KLEIN CHRISTIAN +5

Method for enhancing wound healing

The invention relates to a method for enhancing wound healing in a subject in need thereof, comprising administering to the subject a composition comprising fibronectin type III domain-containing protein 5 (FNDC5) or its cleaved fragment irisin in an amount effective to enhance wound healing
Owner:NAT SUN YAT SEN UNIV

Combinatorial gene construct and non-viral delivery for Anti-obesity

The invention provides a plasmid comprising two or more anti-obesity genes. Also provided by the invention are compositions and host cells comprising the plasmid and methods of increasing the metabolic activity in a mammal. The invention provides a plasmid comprising two or more of (a) a nucleic acid sequence encoding islet amyloid polypeptide (IAPP), (b) a nucleic acid sequence encoding leptin (LEP), and (c) a nucleic acid sequence encoding fibronectin type III domain containing 5 (FNDC5).
Owner:UNIV OF UTAH RES FOUND

A method for establishing an n-glycosylation receptor protein model in Escherichia coli using the skeleton protein fn3

ActiveCN105154462BImprove physical and chemical propertiesImprove physical and chemical properties such as solubilityBacteriaMicroorganism based processesEscherichia coliProkaryote organisms
The invention belongs to the field of biotechnologies, and relates to a method for building efficient N-glycosylation receptor protein models in Escherichia coli by the aid of skeleton proteins Fn3 (fibronectin type III domain). The human-derived proteins Fn3 with N-glycosylation recognition sites are used as receptor proteins. The method includes steps constructing Fn3-Gly recombinant protein gene expression vectors; forming recombinant genes of the N-glycosylation recognition sites carried by the human-derived proteins Fn3; cloning the genes onto the expression vectors capable of secreting the recombinant genes onto pericoel. Recombinant proteins expressed by the vectors can be used as the prokaryote research N-glycosylation receptor protein models for N-glycosylation recombinant research. The method has the advantages that the nearly 100% N-glycosylation recombinant proteins which are good in heat stability, high in expression quantity and convenient to separate and purify can be obtain, excellent protein receptors can be provided for N-glycosylation recombinant engineering, the receptor protein models can be provided for prokaryote N-glycosylation recombinant engineering, and foundation can be laid for efficiently carrying out oligosaccharide chain analysis and function research in late periods of the N-glycosylation recombinant engineering.
Owner:DALIAN UNIV

Antigen Binding Regions Against Fibronectin Type III Domains and Methods of Using The Same

Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.
Owner:JANSSEN BIOTECH INC

Cd8a-binding fibronectin type iii domains

Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
Owner:JANSSEN BIOTECH INC

Antigen Binding Regions Against Fibronectin Type III Domains and Methods of Using the Same

Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.
Owner:JANSSEN BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products